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Mycobacterium bovis bacille Calmette–Guérin (BCG) is listed as an intralesional (IL) 
therapeutic option for inoperable stage III in-transit melanoma in the National Comprehensive 
Cancer Network Guidelines. Although the mechanism is unknown, others have reported 
up to 50% regression of injected lesions, and 17% regression of uninjected lesions in 
immunocompetent patients after direct injection of BCG into metastatic melanoma lesions 
in the skin. BCG and other mycobacteria express ligands capable of stimulating the γ9δ2 
T cells. Therefore, we hypothesized that γ9δ2 T cells play a role in promoting BCG-mediated 
antitumor immunity in patients treated with IL-BCG for in-transit cutaneous melanoma 
metastases. Indeed, we found γ9δ2 T cell infiltration in melanoma skin lesions during the 
course of IL-BCG treatment. Gene expression analysis revealed that BCG injection elicits 
the expression of a vast array of chemokines in tumor lesions, including strong expression 
of CXCL9, 10, and 11, a set of chemokines that attract T cells expressing the CXCR3 
chemokine receptor. In corroboration with our hypothesis, approximately 85% of γδ T cells 
express high levels of CXCR3 on their surface. Importantly, the injected tumor lesions also 
express genes whose protein products are the antigenic ligands for γδ T cells (BTN3A1 and 
MICB), and the cytokines that are the typical products of activated γδ T cells. Interestingly, 
we also found that γδ T  cells infiltrate the regressed lesions that did not receive BCG 
injections. Our study suggests that γ9δ2 T cells may contribute to melanoma regression 
induced by IL-BCG treatment.
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inTrODUcTiOn
Melanoma is a cutaneous malignancy that kills ~10,000 people annually in the US (1). In con-
trast to most other types of cancer in which incidences are steadily declining, the incidence of 
melanoma continues to climb, especially in young patients (1). Melanoma treatment has been strik-
ingly improved through the use of immune-based approaches (2–4), emphasizing the significant 
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protective role of immune cells against melanoma. Intralesional 
(IL) Mycobacterium bovis bacille Calmette–Guérin (BCG), or 
IL-BCG, is currently a recommended therapy in the National 
Comprehensive Cancer Network (NCCN) Guidelines (version 
1.2017) for inoperable stage III in-transit metastatic melanoma. 
Direct injection of BCG into metastatic melanoma lesions in 
the skin has resulted in up to 90% regression of injected lesions 
and 17% regression of uninjected lesions in immunocompetent 
patients (5, 6). Epidermal injection of BCG induces a typical 
delayed hypersensitivity response, characterized by numerous 
chemokines and cytokines and recruitment of a vast array of 
immune cells into the BCG injected sites (7). It is well accepted 
that the immune response plays an important role in IL-BCG-
induced tumor regression.
Mycobacterial infection recruits γδ T  cells to the infected 
lymph nodes during early stages of infection (8). This rapid res-
ponse by γδ T  cells is an important factor in the host control 
of the mycobacterial infection (9, 10). γδ T cells are a subset of 
T cells making up 1–5% of the total CD3+ T cells in peripheral 
blood (11, 12). Unlike αβ TCR lineage, γδ T cells usually do not 
express CD4 or CD8, but only CD3 (11, 13), and direct TCR 
signaling through the associated CD3 complex (14). γδ T  cell 
antigen recognition does not require conventional antigen 
presentation in the context of MHC (15), and they may recog-
nize unconventional antigens including stress molecules like 
MICA and MICB and non-peptide metabolites of isoprenoid 
biosynthesis (16–19). Human γδ T cells can be divided into three 
main populations based on their δ chain expression: Vδ1, Vδ2, 
and Vδ3. γδ T cells expressing Vδ2 chain represent the majority 
of circulating γδ T  cells in healthy human adults, comprising 
50–90% of the peripheral γδ T cell population. The Vδ2 chain 
pairs almost exclusively with Vγ9. Stimulation of PBMCs with 
BCG induces the preferential expansion of the γ9δ2 subset 
(20, 21). This subset of γδ T cells recognizes small non-peptidic 
phosphorylated antigens, such as microbial hydroxymethyl-but-
2-enyl-pyrophosphate (HMBPP) produced by infectious agents 
and recognized as non-self, and induces the production of host 
phosphoantigens, such as isopentenyl pyrophosphate (IPP), the 
intermediates of isoprenoid biosynthesis of mevalonate path-
way, accumulated in infected or transformed cells (19, 22–25). 
Mycobacteria can produce HMBPP and stimulate host cells to 
produce IPP (18). Tumor cells themselves can also express IPP 
to the levels sufficient to activate Vδ2 T cells (26, 27) due to the 
dysfunctional mevalonate pathway in tumors (28). Therefore, 
γδ T  cells not only participate in the control of mycobacterial 
infections but have also displayed a broad cytotoxicity against a 
wide variety of tumor types, including leukemia, neuroblastoma, 
melanoma, and various carcinomas (29–33). Besides their direct 
tumoricidal activity, activated γδ T  cells also display antigen-
presenting cell properties characterized by the expression of high 
levels of HLA-DR and costimulatory molecules such as CD80 and 
CD86 (34, 35) that could support adaptive immune responses 
(36). With all these properties, γδ T cells have been considered 
and evaluated as adoptive immunotherapeutic cells for tumor 
immunotherapy (37–39).
In this study, we investigate whether γδ T cells play a role in 
IL-BCG-induced melanoma regressions.
MaTerials anD MeThODs
Patients and il-Bcg Treatment
Between 2011 and 2013, eight patients studied were diagnosed 
with stage III in-transit melanoma and treated with IL-BCG 
according to the NCCN guidelines. Patient information was 
obtained retrospectively from a single, high volume melanoma 
referral center following internal review board (IRB) approval. 
The goal of treatment was local control and palliation or preven-
tion of symptoms associated with in-transit disease. Following 
a negative tuberculin skin test result, patients were sensitized to 
BCG at distant sites with intradermal injections of BCG to sites 
adjacent to regional nodal basins initially. Following sensitization, 
if applicable, patients then received intradermal BCG injections 
in the target in-transit lesions, typically 2 weeks later. IL injection 
doses following sensitization were typically lower and titrated 
to produce a moderate local inflammatory response to avoid 
skin necrosis and the development of vesicles. These in-transit 
metastases were injected no more frequently than every 2 weeks. 
IL-BCG administration was continued until complete resolution 
or disease progression. The use of patient and healthy donor 
samples was reviewed and approved by Alpha IRB in this study.
immunohistochemistry
The melanoma specimens were obtained by surgical resection 
or open biopsy. Frozen melanoma sections (5-µm thick) were 
fixed in pre-cooled acetone and rinsed with phosphate buffered 
saline at a neutral pH. The tissue sections were blocked with 
normal horse serum. Properly diluted 100  µL of anti-CD3 
(F7.2.38, Dako), γδ TCR (IMMU510, Fisher Scientific), Vγ9 
TCR (7A5, Fisher Scientific), or isotype control antibodies were 
applied on tissue sections. Anti-mouse IgG–HRP conjugate 
was used as a secondary antibody to develop the AEC color of 
specific staining.
rna isolation, cDna Preparation, and 
rna sequencing (rnaseq)
Bacille Calmette–Guérin injected and uninjected melanoma 
biopsies from IL-BCG-treated patients were minced into small 
pieces. Total RNA from both sources was extracted using the 
Qiagen RNeasy mini kit (Qiagen, Valencia, CA, USA). cDNA 
libraries were prepared using TruSeq RNA Library Preparation 
Kit v2 (RS-122-2001) according to the “TruSeq RNA Sample 
Preparation v2 Guide” (Illumina, San Diego, CA, USA). Briefly, 
poly-A+ mRNA was isolated from 300  ng total RNA using 
polyoligo-dT attached on magnetic beads. After fragmentation 
with divalent cations under elevated temperature, the cleaved 
RNA fragments were transcribed into first-strand cDNA using 
reverse transcriptase and random primers. Second-strand cDNA 
was synthesized using DNA polymerase I and RNase H. These 
cDNA fragments were end-repaired, added with single “A” base, 
and ligated with adapters. The products were then purified and 
enriched with PCR to create the final cDNA library. Libraries 
were sequenced on Illumina HiSeq2000 at 50 million reads per 
sample and 1 × 50 read length. These procedures were performed 
by the UCLA Clinical Microarray Core facility.
3Yang et al. BCG and Cutaneous Melanoma Metastases
Frontiers in Oncology | www.frontiersin.org April 2017 | Volume 7 | Article 61
rnaseq Data Processing and analysis
The reads obtained by RNAseq were processed and analyzed with 
specific tools piped together using Ubuntu. Quality assurance 
of reads (GC content, adaptors, and PHRED score assessment) 
were done with FastQC. Trimming to remove poor quality reads 
and adapters was performed using Trimmomatic. The reads were 
scanned with a four base wide sliding window and cut when 
average quality dropped below 15 phred score. Reads less than 36 
bases long were removed. Read-mapping to the human reference 
genome hg19 and abundance estimation of genes and isoforms 
was done using Bowtie2 aligner within RSEM with default values 
(40). We compared the RSEM normalized RPKM/FPKM  values 
of chemokine receptors, cytokines, butyrophilin subfamily 3 
member A1 (BTN3A1), and MHC class-I polypeptide-related 
sequence A and B (MICA and MICB). Vγ9 was quantitated by the 
basic local alignment search tool using a fasta reference down-
loaded from the NCBI database. The Vγ9 counts were normalized 
into counts per million.
T cell composition and Phenotype 
analysis of PBMcs
Frozen PBMCs (0.2–0.5 ×  106/tube) from healthy donors were 
stained with anti-CD3 (APC-H7, BD Biosciences), anti-αβ TCR 
(FITC, BioLegend), and anti-γδ TCR (APC), along with additional 
antibodies, Vγ9 TCR (PE), CXCR3 (CD183) (PE), CCR4 (CD194) 
(PerCP-Cy5.5), CCR6 (CD196) (PerCP-Cy5.5), and CLA (PE). 
The phenotypes of cells were analyzed on BD FACSVerse.
To study the effect of BCG stimulation on the expansion of γδ 
T cells, frozen PBMCs (2.5 × 106/mL/well in a 48-well plate) from 
healthy donors were suspended in T cell culture medium (RPMI-
1640, containing 10% human serum, 1% sodium pyruvate, 1% 
penicillin/streptomycin; Invitrogen, Carlsbad, CA, USA), stimu-
lated with or without BCG live vaccine (TICE BCG University of 
Illinois, IL, USA) at final concentration of 105 colony-forming units/
milliliter. After 6 days in culture at 7% CO2, 37°C, the cells were 
stained with anti-CD3 (APC-H7), anti-γδ TCR (APC), along with 
one of the following additional antibodies: anti-αβ TCR (FITC), 
HLA-DR (FITC), or Vγ9 TCR (PE). The phenotypes of cells were 
analyzed on BD FACSVerse.
isolation and composition analysis of 
Tumor infiltrated lymphocytes (Tils)
Biopsies of regressed and non-regressed melanoma tissue were 
sterilely minced into pieces 1–2  mm in diameter. The minced 
tissue specimens were then attached to the cell foam matrices 
pre-coated with collagen to resemble 3D culture. The tumor 
specimens were cultured in 2 mL of skin T cell medium (Iscove’s 
medium containing 10% fetal bovine serum, 100 U/mL IL-2, and 
10 ng/mL of IL-15) in a 24-well plate. The medium was replaced 
with half of fresh skin T cell medium every other day. After 21 days 
of culture, T cells that migrated out of the melanoma tissue were 
collected. Lymphocyte composition of TILs was analyzed with 
anti-γδ and αβ TCR antibodies by flow cytometry.
statistical analysis
For T cell composition and phenotype analyses by flow cytometry, 
paired Student’s t-test was used as indicated in the figure captions.
For the RNAseq gene expression analysis, immune-related 
genes and housekeeping genes were preselected to reduce false 
discovery rate from multiple hypothesis testing. The differen-
tial expression between BCG injected (n =  9) and uninjected 
(n = 10) was tested using the non-parametric two-sided Mann–
Whitney test. False discovery rate was controlled for by applying 
Benjamini–Hochberg adjustment to resulting p-values. Genes 
meeting the 5% alpha threshold were considered to be statisti-
cally significant. Statistics were performed on R version 3.3.1 and 
plots generated using ggplot2_2.2.0 package.
resUlTs
il-Bcg induces Melanoma regression 
accompanied by γδ T cell infiltration
In this study, eight in-transit stage III melanoma patients were 
treated with IL-BCG as described in the Section “Materials 
and Methods.” As expected, BCG injection induced complete 
or partial regression of injected melanoma lesions in six of 
eight patients (Figure  1A). The details of patients’ response to 
therapy are summarized in Table S1 in Supplementary Material. 
Immunohistological analysis revealed that while CD3 cell infiltra-
tion occurs in both IL-BCG-treated and non-treated lesions, γδ 
T cell infiltration was observed only in the IL-BCG-treated lesions 
(Figure 1B). Some of these infiltrated cells are Vγ9-expressing 
cells (Figure 1B). To verify that an influx of γδ T cells occurred 
with IL-BCG injection, the total RNA samples isolated from these 
lesions were subjected to the high-throughput RNAseq analysis. 
In agreement with the above finding, the Vγ9 gene expression was 
significantly higher in the IL-BCG-treated lesions (Figure  1C) 
according to RNAseq analysis. There were no differences in the 
expression of housekeeping genes such as ER membrane protein 
complex subunit 7 (EMC7), charged multivesicular body protein 
2A (CHMP2A), and chromosome 1 open reading frame 43 
(C1orf43) (Figure 1C and data not shown) (41).
il-Bcg induces chemokines That attract 
cXcr3-expressing T cells; γδ T cells are 
Predominantly cXcr3-expressing cells
Intralesional injection of BCG induces a massive secretion of 
chemokines and cytokines that recruit immune cells (7). We inter-
rogated whether IL-BCG treatment induces chemokines respon-
sible for attracting γδ T cells to injection sites using RNAseq. We 
found that many chemokines were significantly upregulated in 
the IL-BCG-treated tumors (Table 1). Among them, chemokines 
CXCL9, CXCL10, CXCL11 for CXCR3 (CD183), and CCL20 for 
CCR6 (CD196) receptors were all upregulated (Figure 2A; Figure 
S1A and Table S1 in Supplementary Material). Chemokines 
CXCL9, CXCL10, and CXCL11 for CXCR3 receptor showed 
the highest fold changes (approximately 10-fold) and absolute 
increase in gene expression (Figure 2A; Table 1). Corroborating 
that finding, most γδ T  cells from PBMCs express high levels 
of CXCR3 receptors on their surfaces (Figure  2B), while very 
few γδ T cells express CCR4 or CCR6 receptors (Figures S1B,C 
in Supplementary Material). These data suggest that IL-BCG 
FigUre 1 | il-Bcg-induced tumor regression is associated with the presence of γδ T cells. (a) IL-BCG induces tumor regression. Scale bars represent 
1 cm. (B) Presence of γ9 γδ T cells in IL-BCG-injected tumors. Scale bars represent 100 µm. (c) Increased mRNA expression of Vγ9 transcripts in the injected 
tumor tissue by RNA sequencing [fragments per kilobase of exon per million fragments mapped (FPKM)]. EMC7 is a representative housekeeping gene control (41).
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treatment could attract γδ T cells to the injection sites through 
the CXCL9/10/11–CXCR3 chemotaxis axis. Consistent with the 
attraction of γδ T cells, IL-BCG also elicits a significant elevation 
of signature cytokines from γδ T cells, including IFNγ (42, 43), 
TNFα, TNFβ, and IL-15 (44) (Figure 2C; Table 2).
il-Bcg Upregulates local expression of 
Molecules That May Present antigens  
to γδ T cells, and Bcg stimulation 
Preferentially activates and expands  
Vγ9 T cells
Unlike αβ T cells that recognize peptide fragments restricted on 
MHC molecules, γδ T  cells recognize unconventional antigens 
such as normal cellular metabolites of IPP presented on BTN3A1 
(CD277) molecules (19, 22) or the stress-induced MHC class-I 
chain-related molecules, MICA and MICB (45). To investigate 
whether IL-BCG injection induces these γδ T cell targets, we com-
pared the RNA expression profiles between IL-BCG non-injected 
and injected lesions. IL-BCG injection induced the elevated 
expression of both BTN3A1 and MICB molecules (Figure 3A).
To examine whether BCG could activate and expand γδ 
T  cells, we stimulated the PBMCs with live BCG. After 6 days 
of in  vitro stimulation, γδ T  cells were significantly expanded 
in the cultures treated with BCG, but not in the wells without 
BCG (Figure  3A). The newly expanded γδ T  cells expressed a 
high level of HLA-DR, an activation marker for T cells after they 
respond to the cognate antigen stimulation (Figure  3D, solid 
line). Little or no HLA-DR expression was seen on γδ T cells in 
the well without BCG (Figure 3D, shaded area). Also, little or no 
HLA-DR expression was seen on αβ T cells from the well treated 
with BCG (Figure  3D, dashed line). The expanded cells were 
TaBle 1 | expression levels (FPKM) of chemokines in bacille calmette–guérin injected and uninjected melanoma tissue.
chemokine avg.Uninj (10) avg.inj (9) p.value p.adjusted significance
CCL1 0 0.7 --- ---
CCL2 40.8 157.1 0.000 0.000 ***
CCL3 12.4 75.7 0.001 0.005 **
CCL3L1 1.8 9.6 0.082 0.125
CCL3L3 1.7 8.9 0.064 0.101
CCL4 13.1 109.9 0.000 0.001 ***
CCL4L1 2.2 28.4 0.001 0.003 **
CCL4L2 3.1 36 0.001 0.004 **
CCL5 26.7 73.3 0.003 0.008 **
CCL7 0.1 3.1 0.002 0.005 **
CCL8 1.9 22.4 0.000 0.000 ***
CCL11 0.1 2.6 0.002 0.006 **
CCL13 13.3 24.4 0.113 0.159
CCL14 15.2 16.5 0.447 0.514
CCL15 0.1 2 0.002 0.007 **
CCL15–CCL14 0.1 0.3 --- ---
CCL16 1.2 1.1 0.595 0.656
CCL17 1.1 2.2 0.111 0.159
CCL18 54.5 520 0.000 0.001 ***
CCL19 17 56.6 0.017 0.032 *
CCL20 0.3 1.5 0.009 0.021 *
CCL21 17.5 53.6 0.006 0.014 *
CCL22 5.9 12.9 0.079 0.122
CCL23 0.8 2.9 0.016 0.030 *
CCL24 0 0.1 --- ---
CCL25 0 0 --- ---
CCL26 0.9 0.7 0.713 0.767
CCL27 49.2 17 0.156 0.204
CCL28 4.5 2.8 0.102 0.151
CXCL1 3.3 49.4 0.001 0.003 **
CXCL2 1.9 4.9 0.002 0.006 **
CXCL3 0.1 0.7 0.040 0.068
CXCL5 0 31.6 0.000 0.002 **
CXCL6 0 1.9 0.025 0.044 *
CXCL8 0.9 28.2 0.001 0.004 **
CXCL9 48.8 475.3 0.000 0.002 **
CXCL10 41.6 404.3 0.001 0.003 **
CXCL11 3.7 43.8 0.000 0.001 ***
CXCL12 110.6 121.7 0.720 0.767
CXCL13 1 15.1 0.009 0.019 *
CXCL14 446.4 158.1 0.113 0.159
CXCL16 14.7 41.1 0.001 0.003 **
CXCL17 0.1 1.1 0.052 0.084
Differential expression between injected (n = 9) and uninjected (n = 10) were tested using a non-parametric two-sided Mann–Whitney test. Genes were considered significant at the 
5% alpha threshold. Multiple hypothesis testing was accounted for using Benjamini–Hochberg false discovery correction.
Avg.Uninj, average uninjected; Avg.Inj, average injected; p.value, Mann–Whitney test p-value; p.adjusted, Benjamini–Hochberg adjusted p-value.
Significance: *, <0.005; **, <0.01; ***, <0.001.
---, gene was not evaluated because average FPKM levels across samples were less than 0.25.
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predominantly Vγ9-expressing cells (Figures  3B,C). Together, 
these data suggest that BCG preferentially activates γδ T  cells, 
specifically, Vγ9-expressing cells.
γδ T cells infiltrate Uninjected regressed 
Tumor lesions
IL-BCG treatment not only induces the regression of injected 
tumors but also occasionally induces the regression of uninjected 
tumors (Figure 4A) (5, 6). To investigate whether γδ T cells also 
participate in the regression of non-injected in-transit lesions 
during IL-BCG treatment, we compared TILs from regressed and 
non-regressed tumors. Both lesions studied had not been injected 
with BCG (Figure 4A). After 21 days of culture in the presence 
of IL-2 and IL-15, the composition of TILs from regressed 
and non-regressed tissues was analyzed via flow cytometry. 
Figure 4B shows a clear population of γδ T cells in the TILs from 
the regressed melanoma tissue. Interestingly, 72.3% of these γδ 
T cells from regressed melanoma specimens express IFNγ in this 
mixed culture of tumor and TILs without additional stimulation 
(Figure 4C). No such population of γδ T cells was found in TILs 
from adjacent non-regressed melanoma tissue (Figure  4C). 
Similar analysis was performed on the αβ T cell population. αβ 
T cells from both regressed and non-regressed tissues secreted 
minimal levels (0.07 and 0.12%, respectively) of IFNγ (Figure S2 
FigUre 2 | il-Bcg induces secretion of chemokines that attract γδ T cells. (a) Elevation of chemokines that attract CXCR3 expression cells. ***, Student’s 
t-test, p < 0.001. (B) γδ T cells express high levels of CXCR3. Right panel: percentage of γδ and αβ T cells among CD3+ T cells from a representative donor. Middle 
panel: histogram of FACS staining of CXCR3 on γδ T cells (solid line) and αβ T cells (dashed line). Right panel: summary of % of CXCR3+ T cells in αβ T cells and γδ 
T cells, respectively. **, paired t-test, p < 0.01. (c) Elevation of cytokines that can be contributed from activated γδ T cells.
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in Supplementary Material). These data suggest that IFNγ from 
γδ T cells may contribute to tumor regression by IL-BCG.
DiscUssiOn
Bacille Calmette–Guérin has been widely used as an immuno-
therapeutic adjuvant for over 30  years (5, 6). Currently, it is a 
recommended agent for the treatment of bladder cancer and 
melanoma in the NCCN guidelines. Despite this, the mechanisms 
of BCG responses are poorly understood. Previous studies have 
revealed that multiple cellular components and soluble factors 
contribute to the BCG-induced antitumor activity of bladder can-
cer (7), including T cells, natural killer cells, macrophages, dendritic 
cells, and even granulocytes, as well as the soluble factors released 
from these cells. In clinical trials, immune competence is also a 
prerequisite of BCG-induced antitumor activity in melanoma 
(5, 6). Animal studies highlight that CD4 and CD8 T  cells, in 
addition to NK cells, played indispensable roles (7). Lack of these 
cells abolished BCG-induced antitumor activity of BCG vaccina-
tion in bladder cancer in animal models (7, 46, 47). Therefore, 
it is likely that adjuvant therapy with BCG induces multilayer 
antitumor activities. Discovering what is behind these antitumor 
activities is essential to optimizing the therapeutic effects of 
adjuvant BCG therapy. Few studies have focused on the role 
played by γδ T cells in BCG-induced antitumor activity (35). γδ 
T cells comprise a small proportion of T cells that have limited 
T cell receptor diversity and unconventional, MHC-independent, 
antigen-recognition mechanisms. The role of γδ T cells in tumor 
immunology has not been fully appreciated when compared 
to αβ T  cells. Here, we found that IL-BCG treatment induces 
a response that has the capacity to actively attract γδ T  cells, 
selectively expand Vγ9 T  cells, and upregulate antigens recog-
nized by Vγ9Vδ2 T cells in injected lesions. These data suggest 
that γδ T cells are strongly associated with the antitumor activity 
induced by IL-BCG. Furthermore, γδ T cells are also present in 
regressed lesions that are not injected with BCG. This association 
suggests a primary role of γδ T cells in the induction of melanoma 
regressions (48).
It has been reported that γδ T cells play a critical role in the 
control of mycobacterial infections in both humans and animals 
TaBle 2 | expression levels of cytokines in bacille calmette–guérin injected and uninjected melanoma tissues.
cytokine name avg.Uninj (10) avg.inj (9) p.value p.adjusted significance
GMCSF 0.2 1 0.019 0.035 *
IFNα 0 0 --- ---
IFNβ 0 0 --- ---
IFNγ 0.9 7.4 0.004 0.011 *
IL-1A 0.2 1.9 0.002 0.006 **
IL-1B 1 82.7 0.000 0.001 ***
IL-1F10 1 0.3 0.281 0.353
IL-2 0 0.2 --- ---
IL-3 0.1 0 --- ---
IL-4 0.1 0 --- ---
IL-5 0 0.1 --- ---
IL-6 1.1 20.2 0.002 0.006 **
IL-6ST 32.1 36.2 0.400 0.466 *
IL-7 1.6 2.6 0.050 0.082
IL-8 (CCL8) 1.9 22.4 0.000 0.000 ***
IL-9 0.1 0.1 --- ---
IL-10 1.8 3.5 0.006 0.014 *
IL-11 0.3 0.3 0.713 0.767
IL-12B 0.1 0.4 0.016 0.030 *
IL-13 0.1 0.1 --- ---
IL-14 15.1 15.2 0.968 0.974
IL-15 2 8.9 0.000 0.002 **
IL-16 7.6 6.1 0.133 0.177
IL-17A 0 0 --- ---
IL-17B 0.1 0.3 --- ---
IL-17C 0 0 --- ---
IL-17D 6.9 0.8 0.002 0.006 **
IL-17F 0 0 --- ---
IL-18 39.4 42.1 0.400 0.466
IL-18BP 12.2 45.5 0.001 0.003 **
IL-19 0 0.1 --- ---
IL-20 0 0.5 --- ---
IL-21 0 0.1 --- ---
IL-21-AS1 0 0.1 --- ---
IL-22 0 0.1 --- ---
IL-23A 0.1 0.8 0.007 0.016 *
IL-24 0.1 2 0.014 0.027 *
IL-25 0 0 --- ---
IL-26 0.1 0.7 0.001 0.004 **
IL-27 0 0.2 --- ---
IL-28 0 0 --- ---
IL-29 0.1 0 --- ---
IL-31 0 0 --- ---
IL-32 9.4 52.7 0.000 0.001 ***
IL-33 7.8 13.1 0.243 0.310
IL-34 4 1.5 0.315 0.387
IL-36A 0 0.1 --- ---
IL-36B 1 1 0.902 0.919
IL-36G 4.3 3.1 0.967 0.974
IL-37 14.9 2.1 0.108 0.158
TGFβ1 2.9 5.8 0.004 0.011 *
TGFβ2 7 1.5 0.065 0.103
TGFβ3 6 11.8 0.028 0.048 *
TNFα 2.2 9.2 0.000 0.000 ***
TNFβ 0.2 1.3 0.001 0.004 **
Differential expression between injected (n = 9) and uninjected (n = 10) were tested using a non-parametric two-sided Mann–Whitney test. Genes were considered significant at the 
5% alpha threshold. Multiple hypothesis testing was accounted for using Benjamini–Hochberg false discovery correction.
Avg.Uninj, average uninjected; Avg.Inj, average injected; p.value, Mann–Whitney test p-value; p.adjusted, Benjamini–Hochberg adjusted p-value.
Significance: *, <0.005; **, <0.01; ***, <0.001.
---, gene was not evaluated because average FPKM levels across samples were less than 0.25.
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(49, 50). Primary M. bovis BCG infection induces major clonal 
expansion of phosphoantigen-specific Vγ2Vδ2 (also termed as 
Vγ9Vδ2) T cells (51, 52). In this study, we confirmed that BCG 
preferentially activates and expands Vγ9 γδ T  cells in PBMC 
in vitro, with more than a 20-fold expansion in 6-day stimulation 
from frozen PBMCs (Figure  3B). Meanwhile, very few CD3+ 
αβ T  cells were activated and expanded from these PBMCs 
(Figure 3D). This rapid, preferential activation of Vγ9 γδ T cells 
AB
C
D
FigUre 3 | continued
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FigUre 4 | il-Bcg induces tumor regressions in uninjected melanoma lesions. (a) IL-BCG induces regression of uninjected lesions. Upper left: in-transit 
melanoma metastases at the time of first IL-BCG treatment. Upper middle: 8 weeks post-IL-BCG, tumors exhibit mild to moderate inflammation. Upper right: 
13 weeks post-IL-BCG. Adjacent uninjected tumors (white arrows) exhibiting regression (R) or non-regression (NR). (B) Presence of γδ T cells in regressed but not 
non-regressed uninjected melanoma lesions. (c) IFNγ secretion of tumor infiltrated by γδ T cells. Tumors infiltrated by γδ T cells secrete IFNγ isolated from regressed 
but not non-regressed uninjected melanoma lesions.
FigUre 3 | continued   
il-Bcg injection induces the elevated expression of target antigens for γδ T cells, bacille calmette–guérin (Bcg) stimulation preferentially activates 
and expands γ9δ2 T cells. (a) IL-BCG induces the elevated expression of antigens for γδ T cells. (B) BCG stimulation expands γδ T cells preferentially. Left panel: 
histogram of FACS staining on γδ T cells without BCG stimulation for 6 days. Middle panel: histogram of FACS staining on γδ T cells with BCG stimulation for 
6 days. Right panel: summary of percentage of γδ+ T cells without or with BCG stimulation for 6 days. **, paired t-test, p < 0.01. (c) BCG expanded γδ T cells are 
predominantly Vγ9+ cells. Left panel: a representative histogram of FACS staining on Vγ9. Right panel: summary of percentage of Vγ9+ cells in γδ T cells treated 
with or without BCG. *, paired t-test, p < 0.05. (D) BCG preferentially activates γδ T cells, not αβ T cells. Left panel: a representative histogram of FACS staining on 
HLA-DR. Right panel: summary of percentage of HLA-DR+ cells for γδ T cells with or without BCG stimulation and αβ T cells with BCG stimulation. ***, paired t-test, 
p < 0.001; ****, paired t-test, p < 0.0001.
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is not only consistent with the role γδ T cells play in the early 
control of mycobacterial infections (9, 10) but also provides a 
mechanism by which Vγ9Vδ2 T  cells could impact antitumor 
activity (38, 48).
Target antigens for Vγ9Vδ2 T cells are phosphoantigens, the 
low molecular weight metabolites of the mevalonate pathway 
(19, 22). Infection and physiologic stress can cause dysregulation 
of the mevalonate pathway and induce elevated phosphoantigen 
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metabolism. Meanwhile, infection and stress also induce 
expression of the BTN3A family of molecules, putative molecules 
that present phosphoantigens to Vγ9Vδ2 T cells (22). It is not sur-
prising, therefore, that IL-BCG treatment can induce melanoma 
regression at injected sites, and that these regressions are strongly 
associated with the presence of Vγ9Vδ2 T  cells (48). Besides 
infection, tumors are stressed due to rapid growth, limited oxy-
gen and nutrient supplies. These physiologic stressors also induce 
dysregulation of the mevalonate pathway and expression of 
BTN3A proteins (22). Since BCG preferentially activates and 
expands Vγ9Vδ2 T cells in a locoregional manner, it is perceiv-
able that some Vγ9Vδ2 T  cells could migrate to the stressed 
tumor itself and execute antitumor activity in non-injected 
lesions. In addition to mediating the expression of BTN3A for 
γδ T cell response, BCG therapy also enhances the expression 
of MIC B in injected tumor lesions (Figure 3A), another target 
Ag for γδ T cells and NK T cells (7). The main point of our study 
was to investigate the role of γδ T cells on the activity induced by 
IL-BCG treatment but was not intended to exclude the potential 
role of other cells. We cannot rule out that NK cells may also 
contribute to the observed regression, and future studies are 
warranted to determine the mechanism of regression to answer 
whether γδ T cells actively lyse the tumors or influence the tumor 
cells to limit growth in other ways. Since NK cells are known to 
have these capabilities, their potential role in BCG cannot be 
ruled out.
Bacille Calmette–Guérin infection or vaccination induces 
strong delayed type hypersensitivity responses (7), a typical Th1 
type response. This response recruits diversified inflammatory 
cells and stimulates the release of a variety of cytokines and 
chemokines. IL-BCG treatment induces a long-lasting high-
level release of chemokines such as CXCL9, 10, and 11, a set of 
chemokines that recruit CXCR3 expression cells. Interestingly, 
90% of γδ T cells in the peripheral blood express high levels of 
CXCR3 receptors. This observation further supports the conclu-
sion that IL-BCG can recruit γδ T  cells to the injected lesions 
and expand the Vγ9Vδ2 T cell subset. This observation further 
supports the conclusion that IL-BCG can recruit γδ T cells to the 
injected lesions and expand the Vγ9Vδ2 T cell subset.
Cytokines are the mediators of immune cells that execute the 
activity of immune responses. Among the long list of cytokines 
expressed at BCG-injected tumor lesions (Table 2), the expres-
sion of several cytokines, IFNγ (42, 43), IL-15 (44), and TNFα, 
accompany the increase in γδ T  cells. These cytokines can 
have direct and indirect antitumor activities during immune 
responses (7). Therefore, expression of these cytokines (despite 
the fact that they are not unique for γδ T  cells and can be 
expressed by NK cells and other αβ T helper cells) also cor-
roborates the hypothesized positive role of γδ T cells in BCG-
induced antitumor activity. Alternately, BCG is live vaccine 
that can induce strong cellular immune responses. As negative 
feedback of these immune responses, it is expected that BCG 
injection will induce the expression of regulatory factors, such 
as immunosuppressive cytokines that can downregulate anti-
tumor activity. IL-17 is a product of regulatory γδ T cells during 
the early phase of immune response (53, 54). IL-17-producing 
regulatory γδ T cells have been shown to mediate pro-tumor 
activities in mouse models (53, 54). Interestingly, the expres-
sion of IL-17 (only IL-17D isoform) is clearly downregulated in 
BCG-injected melanoma lesions (Table 2). It is possible that 
the time of sample collection is out of IL-17 expression phase, 
or BCG recruited γ9δ2 subset is effector γδ T  cells (53–55). 
Nevertheless, this observation also supports the notion of a 
positive role of γδ T  cells in BCG-induced antitumor activ-
ity. However, BCG injection does induce the expression of 
cytokines that play pro-tumor activities, including IL-1β, 6, 
8, 10, 18BP (56), 26, 32 (57), and TGFβ (58, 59) (Table  2). 
Whether all or part of these cytokines are produced by γδ 
T  cells in BCG-injected lesions is unknown. This will be an 
important topic for the future study to improve the efficacy 
of BCG therapy, since BCG therapy does not always eradicate 
melanoma completely.
IL-BCG therapy can induce regression of injected and unin-
jected melanoma lesions, but durable clinical responses are not 
observed in all treated patients. The limited effect of this treatment 
may be due to the transient nature of the inflammatory response 
induced. We found the highest expression of chemokines and 
cytokines in BCG-treated melanoma skin metastases 4  weeks 
after IL-BCG injection are CCL2 (40.8 vs. 157.1, of the average 
FPKM in BCG uninjected vs. BCG injected melanoma tissues), 
CCL3 (12.4 vs. 75.7), CCL4 (13.1 vs. 109.9), CCL5 (26.7 vs. 73.3), 
CCL18 (54.5 vs. 520), CXCL9 (48.8 vs. 475.3), and CXCL10 
(41.6 vs. 404.3) (Table 1). These chemokines are usually released 
from the monocyte/macrophage lineage and mast cells during 
the acute phase of the inflammatory immune response (60, 61). 
High-level expression of these chemokines not only recruits 
and activates type 1 macrophages and neutrophils (60) but also 
recruits immune regulatory cells such as T regulatory cells through 
CCL2, CCL18 chemotaxis (60, 62, 63), myeloid-derived suppres-
sor cells (60, 62, 63), and type 2 neutrophils (60, 64) through 
CCL2, CCL3, CCL4, and CCL5 chemotaxis. These immunosup-
pressive cells may counter any antitumor immune responses. On 
the other hand, high-level expression of CXCL9 and CXCL10 
recruit Th1 CD4 cells, cytotoxic CD8 T cells, NK cells, and γδ 
T  cells, through the CXCL9 and CXCL10/CXCR3 chemotactic 
axis (60). Activation of these cells can stimulate IFNγ, IL-6, IL-8, 
IL-10, IL-15, IL-18BP, IL-32, TGFβ1, TGFβ3, and TNFα release 
as the average FKPMs of most of cytokines are below 10 (Table 2) 
in contrast to 100–500 for the chemokines (Table 1). Whatever 
the source, a substantial number of cytokines induced by IL-BCG 
favor the tumor, such as IL-1β (65), IL-6 (66), IL-8 (67), IL-10, 
IL-18BP (65), IL-32 (57, 68), and TGFβ (55, 56). Even TNFα and 
IFNγ may have dual effects. For example, at high concentrations, 
TNFα can kill sarcoma cells by binding to the TNFR1 and induc-
ing apoptosis (58). In contrast, at sustained low levels, TNFα 
promotes tumorigenesis by inducing the generation of reactive 
oxygen and nitrogen species to induce DNA damage (58). IFNγ 
can activate cytotoxic T cells and macrophages to kill tumor cells; 
meanwhile, persistent expression of IFNγ can induce expression 
of immune checkpoint molecules such as PD-L1 on tumor cells 
and antigen-presenting cells to diminish T cell antitumor activi-
ties (69). How the combination of cytokines, chemokines, and 
the cells they recruit to the local tumor microenvironment lead 
to tumor progression or regression has yet to be understood and 
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